Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
Codexis (Nasdaq:CDXS) announced it will report its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call and webcast for discussing the results will be held at 4:30 p.m. ET. Participants can join the live call by dialing 877-705-2976 (domestic) or (201) 689-8798 (international). The webcast will be available for archiving for 90 days. Codexis leverages its proprietary CodeEvolver platform for novel enzyme development impacting various industries.
- Scheduled financial results presentation indicates transparency and commitment to shareholders.
- Use of proprietary CodeEvolver platform suggests strong potential for innovation and market advantage.
- None.
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or (201) 689-8798 (international), conference ID #13726635. A replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international) conference ID #13726635.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021, and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact:
Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com
FAQ
When will Codexis report its fourth quarter and fiscal year 2021 financial results?
What time is the Codexis conference call on February 24, 2022?
How can I access the Codexis live webcast?
What is the significance of the CodeEvolver platform for Codexis?
